These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 24619496)

  • 1. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
    Simó M; Argyriou AA; Macià M; Plans G; Majós C; Vidal N; Gil M; Bruna J
    Cancer Chemother Pharmacol; 2014 May; 73(5):919-23. PubMed ID: 24619496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.
    Chamberlain MC; Glantz MJ; Fadul CE
    Neurology; 2007 Sep; 69(10):969-73. PubMed ID: 17785665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
    Norden AD; Ligon KL; Hammond SN; Muzikansky A; Reardon DA; Kaley TJ; Batchelor TT; Plotkin SR; Raizer JJ; Wong ET; Drappatz J; Lesser GJ; Haidar S; Beroukhim R; Lee EQ; Doherty L; Lafrankie D; Gaffey SC; Gerard M; Smith KH; McCluskey C; Phuphanich S; Wen PY
    Neurology; 2015 Jan; 84(3):280-6. PubMed ID: 25527270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of unresectable skull base meningiomas with somatostatin analogs.
    Schulz C; Mathieu R; Kunz U; Mauer UM
    Neurosurg Focus; 2011 May; 30(5):E11. PubMed ID: 21529167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.
    Johnson DR; Kimmel DW; Burch PA; Cascino TL; Giannini C; Wu W; Buckner JC
    Neuro Oncol; 2011 May; 13(5):530-5. PubMed ID: 21558077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
    Graillon T; Sanson M; Campello C; Idbaih A; Peyre M; Peyrière H; Basset N; Autran D; Roche C; Kalamarides M; Roche PH; Fuentes S; Tabouret E; Barrie M; Cohen A; Honoré S; Boucekine M; Baumstarck K; Figarella-Branger D; Barlier A; Dufour H; Chinot OL
    Clin Cancer Res; 2020 Feb; 26(3):552-557. PubMed ID: 31969329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas.
    Chamberlain MC; Glantz MJ
    Cancer; 2008 Oct; 113(8):2146-51. PubMed ID: 18756531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Mazza E; Brandes A; Zanon S; Eoli M; Lombardi G; Faedi M; Franceschi E; Reni M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):115-20. PubMed ID: 26659583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
    Seystahl K; Stoecklein V; Schüller U; Rushing E; Nicolas G; Schäfer N; Ilhan H; Pangalu A; Weller M; Tonn JC; Sommerauer M; Albert NL
    Neuro Oncol; 2016 Nov; 18(11):1538-1547. PubMed ID: 27106404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
    Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
    Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaplastic meningioma: octreotide therapy for a case of recurrent and progressive intracranial disease.
    Rammo R; Rock A; Transou A; Raghunathan A; Rock J
    J Neurosurg; 2016 Feb; 124(2):496-500. PubMed ID: 26274993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
    Schrell UM; Rittig MG; Anders M; Koch UH; Marschalek R; Kiesewetter F; Fahlbusch R
    J Neurosurg; 1997 May; 86(5):840-4. PubMed ID: 9126900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
    Mason WP; Gentili F; Macdonald DR; Hariharan S; Cruz CR; Abrey LE
    J Neurosurg; 2002 Aug; 97(2):341-6. PubMed ID: 12186462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic LINAC radiosurgery for incompletely resected or recurrent atypical and anaplastic meningiomas.
    El-Khatib M; El Majdoub F; Hoevels M; Kocher M; Müller RP; Steiger HJ; Sturm V; Maarouf M
    Acta Neurochir (Wien); 2011 Sep; 153(9):1761-7. PubMed ID: 21706274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spot scanning-based proton therapy for intracranial meningioma: long-term results from the Paul Scherrer Institute.
    Weber DC; Schneider R; Goitein G; Koch T; Ares C; Geismar JH; Schertler A; Bolsi A; Hug EB
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):865-71. PubMed ID: 22138457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence of intracranial meningioma after surgery: analysis of influencing factors and outcome.
    Bumrungrachpukdee P; Pruphetkaew N; Phukaoloun M; Pheunpathom N
    J Med Assoc Thai; 2014 Apr; 97(4):399-406. PubMed ID: 24964682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary metastases in patients with recurrent, treatment-resistant meningioma: prognosis and identification by ¹¹¹Indium-octreotide imaging.
    Alexandru D; Glantz MJ; Kim L; Chamberlain MC; Bota DA
    Cancer; 2011 Oct; 117(19):4506-11. PubMed ID: 21446045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in the recurrence of meningiomas by combining somatostatin receptor scintigraphy of (99m)Tc-HYNIC-octreotide SPECT/CT and radio guidance with a hand-held γ-probe during surgery.
    Wang S; Yang W; Deng J; Zhang J; Ma F; Wang J
    Nucl Med Commun; 2013 Mar; 34(3):249-53. PubMed ID: 23276828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
    Kaley TJ; Wen P; Schiff D; Ligon K; Haidar S; Karimi S; Lassman AB; Nolan CP; DeAngelis LM; Gavrilovic I; Norden A; Drappatz J; Lee EQ; Purow B; Plotkin SR; Batchelor T; Abrey LE; Omuro A
    Neuro Oncol; 2015 Jan; 17(1):116-21. PubMed ID: 25100872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic radiosurgery of World Health Organization grade II and III intracranial meningiomas: treatment results on the basis of a 22-year experience.
    Pollock BE; Stafford SL; Link MJ; Garces YI; Foote RL
    Cancer; 2012 Feb; 118(4):1048-54. PubMed ID: 21773968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.